Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,801,624
  • Shares Outstanding, K 2,494,212
  • Annual Sales, $ 41,140 M
  • Annual Income, $ 4,836 M
  • 60-Month Beta 0.68
  • Price/Sales 3.08
  • Price/Cash Flow 11.50
  • Price/Book 5.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.70
  • Number of Estimates 4
  • High Estimate 0.73
  • Low Estimate 0.68
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -11.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.04 +2.58%
on 01/07/20
48.25 -2.11%
on 01/24/20
+0.33 (+0.70%)
since 12/24/19
3-Month
43.41 +8.80%
on 11/15/19
48.25 -2.11%
on 01/24/20
+3.21 (+7.29%)
since 10/24/19
52-Week
38.16 +23.77%
on 01/28/19
48.25 -2.11%
on 01/24/20
+8.86 (+23.09%)
since 01/24/19

Most Recent Stories

More News
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma

Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.

RHHBY : 41.2000 (-2.81%)
GSK : 47.23 (-1.23%)
ALXN : 105.27 (-3.02%)
EPZM : 22.40 (-16.17%)
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

MRK : 85.98 (-2.91%)
PFE : 39.82 (-2.19%)
AZN : 49.28 (-1.83%)
RHHBY : 41.2000 (-2.81%)
GSK : 47.23 (-1.23%)
JNJ : 148.32 (-0.14%)
NVS : 93.87 (-1.11%)
Global Epilepsy Therapeutics Market 2020 – Abbott Laboratories , GlaxoSmithKline plc , Cephalon , Johnson & Johnson , Pfizer

ABT : 90.40 (-0.36%)
GSK : 47.23 (-1.23%)
NVS : 93.87 (-1.11%)
VRX.TO : 30.80 (-3.33%)
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review

Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.

GSK : 47.23 (-1.23%)
RHHBY : 41.2000 (-2.81%)
PFE : 39.82 (-2.19%)
LLY : 139.07 (-1.52%)
Varicella Zoster Infection Treatment Market 2020 Global Trends, Statistics, Size, Share, Regional Analysis By 2025-MRE Report

The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it...

ABT : 90.40 (-0.36%)
GSK : 47.23 (-1.23%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
TEVA : 10.10 (-2.79%)
VRX.TO : 30.80 (-3.33%)
Keloid Treatment Market 2020 Global Trends, Statistics, Size, Share, Regional Analysis By 2025-MRE Report

Global share consists of several players including Pacific World Corporation, Revitol Corporation Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Novartis AG, Renovo Group plc., Valeant Pharmaceuticals...

AVMXY : 7.8900 (+9.13%)
BMY : 64.16 (-4.05%)
GALE : 0.26 (-7.14%)
GSK : 47.23 (-1.23%)
NVS : 93.87 (-1.11%)
PRGO : 58.76 (-1.21%)
SNOA : 5.69 (+9.85%)
VRX.TO : 30.80 (-3.33%)
Gastro Esophageal Reflux Disease Drug and Devices Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 49.28 (-1.83%)
BSX : 43.21 (-0.83%)
CEMP : 2.33 (+1.30%)
STIM : 4.19 (-1.87%)
GSK : 47.23 (-1.23%)
IRWD : 12.37 (-3.59%)
MDGS : 1.87 (unch)
MDT : 119.26 (-1.41%)
MRK : 85.98 (-2.91%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

-- Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory...

GSK : 47.23 (-1.23%)
ASEAN Dietary Supplements Market Size to Reach USD 10.60 Billion by 2026; Increasing Health Consciousness among the Urban Populace to Fuel the Market: Fortune Business Insights(TM)

The Southeast Asia Dietary Supplements Market size is set to reach USD 10.60 billion by 2026, exhibiting a CAGR of 5.60% during the forecast period. Increasing prevalence of lifestyle-induced disorders,...

ADM : 44.30 (-1.49%)
GSK : 47.23 (-1.23%)
NSRGY : 111.8550 (+0.14%)
NUS : 36.41 (-3.52%)
OTSKY : 22.4350 (+0.11%)
PFE : 39.82 (-2.19%)
Childhood Absence Epilepsy Therapeutics Market Analysis and Demand With Forecast Overview to 2026

Big Market Research has added a report, titled, “” The report not only provides a comprehensive analysis of market overview and dynamics for the historical period, 2019-2026, but also offers global...

GSK : 47.23 (-1.23%)
NVS : 93.87 (-1.11%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 48.59
1st Resistance Point 47.91
Last Price 47.23
1st Support Level 46.89
2nd Support Level 46.55

See More

52-Week High 48.25
Last Price 47.23
Fibonacci 61.8% 44.40
Fibonacci 50% 43.21
Fibonacci 38.2% 42.01
52-Week Low 38.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar